the difference is in magnitude and immediacy of effect
Alternatively, they were provided with a Dexcom G6 device for the purpose of continuous glucose monitoring [2]
Pharmacological management of obesity: an endocrine Society clinical practice guideline
Tirzepatide Side Effects# Well-characterized from Phase 3 (SURPASS, SURMOUNT) trials and post-market surveillance: Gastrointestinal : Nausea (12-33%), diarrhea (12-21%), vomiting (5-12%), constipation (6-11%) Decreased appetite : Common and expected pharmacological effect Injection site reactions : Mild, occurring in 2-5% of patients Pancreatitis : Rare
Formulation matters a lot: Copper peptides become inactive in the presence of strong chelating agents or low-pH acids
NICE NG28 and the MHRA advise considering B12 monitoring in long-term metformin users who have symptoms or risk factors for deficiency, as metformin can impair B12 absorption in the terminal ileum